Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Risk of hip/femur fracture after stroke: a population-based case-control study.

Pouwels S, Lalmohamed A, Leufkens B, de Boer A, Cooper C, van Staa T, de Vries F.

Stroke. 2009 Oct;40(10):3281-5. doi: 10.1161/STROKEAHA.109.554055. Epub 2009 Aug 6.

2.

Treatment for osteoporosis in people with ß-thalassaemia.

Bhardwaj A, Swe KM, Sinha NK, Osunkwo I.

Cochrane Database Syst Rev. 2016 Mar 10;3:CD010429. doi: 10.1002/14651858.CD010429.pub2. Review.

PMID:
26964506
3.

Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies.

Liu J, Zhang HX, Lu XX, Hu JJ, Deng LF.

Genet Test Mol Biomarkers. 2014 Feb;18(2):117-22. doi: 10.1089/gtmb.2013.0331. Epub 2013 Nov 8. Review.

4.

Bisphosphonates for osteoporosis in people with cystic fibrosis.

Conwell LS, Chang AB.

Cochrane Database Syst Rev. 2014 Mar 14;(3):CD002010. doi: 10.1002/14651858.CD002010.pub4. Review.

PMID:
24627308
5.

Bisphosphonates for osteoporosis in people with cystic fibrosis.

Conwell LS, Chang AB.

Cochrane Database Syst Rev. 2012 Apr 18;(4):CD002010. doi: 10.1002/14651858.CD002010.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;(3):CD002010.

PMID:
22513903
6.

Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.

Iwamoto J, Matsumoto H, Takeda T.

Curr Med Res Opin. 2008 May;24(5):1379-84. doi: 10.1185/030079908X297321 . Epub 2008 Apr 1. Review.

PMID:
18384711

Supplemental Content

Support Center